A drug transporter for all ages? ABCB1 and the developmental pharmacogenetics of cyclosporine

Pharmacogenomics

Volumn 9, Issue 6, 2008, Pages 783-789

  Hesselink, Dennis A ^a   van Schaik, Ron H N ^a   Nauta, Jeroen ^b   van Gelder, Teun ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b SOPHIA CHILDREN S HOSPITAL   (Netherlands)

Author keywords

ABCB1; Calcineurin inhibitor; Cyclosporine; Cytochrome P450 3A; Immunosuppressant; Kidney; P glycoprotein; Pharmacogenetics; Single nucleotide polymosphism; Transplantation

Indexed keywords

CELL NUCLEUS RECEPTOR; CYCLOSPORIN; CYCLOSPORIN A; CYSTEINE; CYTOCHROME P450 3A4; CYTOCHROME P450 3A5; GLYCINE; GLYCOPROTEIN P; MULTIDRUG RESISTANCE PROTEIN 1; MULTIDRUG RESISTANCE PROTEIN 2; ORGANIC ANION TRANSPORTER 2; THREONINE; ABCB1 PROTEIN, HUMAN; IMMUNOSUPPRESSIVE AGENT;

ADOLESCENT; AGE; ALLELE; AMINO ACID SUBSTITUTION; AREA UNDER THE CURVE; ARTICLE; CARDIOVASCULAR DISEASE; CHILD; DIABETES MELLITUS; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISPOSITION; DRUG DISTRIBUTION; DRUG DOSAGE FORM COMPARISON; DRUG METABOLISM; DRUG MONITORING; DRUG TRANSPORT; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; GINGIVA HYPERPLASIA; HAPLOTYPE; HETEROZYGOSITY; HIRSUTISM; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; HYPERTRICHOSIS; IMMUNOSUPPRESSIVE TREATMENT; INDIVIDUALIZATION; INFECTION SENSITIVITY; KIDNEY DISEASE; KIDNEY FAILURE; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; MALIGNANT NEOPLASTIC DISEASE; PATIENT CARE; PATIENT COMPLIANCE; PHARMACOGENETICS; PREDICTION; SIDE EFFECT; ADULT; AGING; DRUG DETOXIFICATION; GENETICS; SINGLE NUCLEOTIDE POLYMORPHISM;

ADULT; AGING; CHILD; CYCLOSPORINE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; METABOLIC DETOXICATION, DRUG; P-GLYCOPROTEIN; PHARMACOGENETICS; POLYMORPHISM, SINGLE NUCLEOTIDE;

EID: 48949119314     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/14622416.9.6.783     Document Type: Article

References (55)

1. Fanta S, Niemi M, Jönsson S et al.: Pharmacogenetics of cyclosporine in children suggests an age-dependent influence of ABCB1 polymorphisms. Pharmacogenet. Genomics 18(2), 77-90 (2007).
2. Wolfe RA, Ashby VB, Milford EL et al.: Comparison of mortality in all patients on dialysis, patients on dialysis awaiting transplantation, and recipients of a first cadaveric transplant. N. Engl. J. Med. 341(23), 1725-1730 (1999).
3. McDonald SP, Craig JC: Long-term survival of children with end-stage renal disease. Australian and New Zealand Paediatric Nephrology Association. N. Engl. J. Med. 350(26), 2654-2662 (2004).
4. Milliner DS: Pediatric renal-replacement therapy: coming of age. N. Engl. J. Med. 350(26), 2637-2639 (2004).
5. Hariharan S, Johnson CF, Bresnahan BA, Taranto SE, McIntosh MJ, Stablein D: Improved graft survival after renal transplantation in the United States, 1988 to 1996. N. Engl. J. Med. 342(9), 605-612 (2000).
6. Meier-Kriesche HU, Schold JD, Srinivas TR, Kaplan B: Lack of improvement in renal allograft survival despite a marked decrease in acute rejection rates over the most recent era. Am. J. Transplant 4, 378-383 (2004).
7. Groothoff JW, Gruppen MP, Offringa M et al.: Mortality and causes of death of end-stage renal disease in children: a Dutch cohort study. Kidney Int. 61, 621-629 (2002).
8. Hesselink DA, Smak Gregoor PJH, Weimar W: The use of cyclosporine in renal transplantation. Transplant. Proc. 36(Suppl. 2), S99-S106 (2004).
9. Meier-Kriesche HU, Li S, Gruessner RWG et al.: Immunosuppression: evolution in practice and trends, 1994-2004. Am. J. Transplant 6(Part 2), 1111-1131 (2006).
10. Marks SD: How have the past 5 years of research changed clinical practice in paediatric nephrology? Arch. Dis. Child. 92, 357-361 (2007).
11. Dantal J, Hourmant M, Cantarovich D et al.: Effect of long-term immunosuppression in kidney-graft recipients on cancer incidence: randomised comparison of two cyclosporin regimens. Lancet 351, 623-628 (1998).
12. Fishman JA, Rubin RH: Infection in organ-transplant recipients. N. Engl. J. Med. 338(24), 1741-1751 (1998).
13. Nankivell BJ, Borrows, RJ, Fung CLS, O'Connell PJ, Allen RDM, Chapman JR: The natural history of chronic allograft nephropathy. N. Engl. J. Med. 349(24), 2326-2333 (2003).
14. Webb NJA, Johnson R, Postlethwaite RJ: Renal transplantation: present outocmes and future challenges. Arch. Dis. Child. 88, 844-847 (2003).
15. Ptachcinski RJ, Venkataramanan R, Rosenthal JT, Burckart GJ, Taylor RJ, Hakala TR: Cyclosporine kinetics in renal transplantation. Clin. Pharmacol. Ther. 38, 296-300 (1985).
16. Lindholm A, Kahan BD. Influence of cyclosporine pharmacokinetics, trough concentrations, and AUC monitoring on outcome after kidney transplantation. Clin. Pharmacol. Ther. 54, 205-218 (1993).
17. Kovarik JM, Mueller EA, Richard F et al.: Evidence for earlier stabilization of cyclosporine pharmacokinetics in de novo renal transplant patients receiving a microemulsion formulation. Transplantation 62, 759-763 (1996).
18. Keown P, Landsberg D, Halloran P et al.: A randomized, prospective multicenter pharmacoepidemiologic study of cyclosporine microemulsion in stable renal graft recipients: report of the Canadian Neoral Renal Transplant Study Group. Transplantation 62, 1744-1752 (1996).
19. Fanta S, Jönsson S, Backman JT, Karlsson MO, Hoppu K: Developmental pharmacokinetics of ciclosporin: a population pharmacokinetic study in paediatric renal transplant candidates. Br. J. Clin. Pharmacol. 64(6), 772-784 (2007).
20. Hoppu K, Koskimies O, Holmberg C, Hirvisalo EL: Evidence for pre-hepatic metabolism of oral cyclosporine in children. Br. J. Clin. Pharmacol. 32, 477-481 (1991).
21. Del Mar Fernández de Catta M, Santos-Buelga D, Dominguez-Gil A, Garcia MJ: Immunosuppressive therapy for paediatric transplant patients: pharmacokinetic considerations. Clin. Pharmacokinet. 41(2), 115-135 (2002).
22. Clase CM, Mahalati K, Kiberd BA et al.: Adequate early cyclosporin exposure is critical to prevent renal allograft rejection: patients monitored by absorption profiling. Am. J. Transplant 2, 789-795 (2002).
23. Talautikar GS, John GT, Selvakumar R, job V, Thomas PP. Jacob CK: Pre- and postrenal transplantation pharmacokinetics of cyclosporine microemulsion. Transplant Proc. 35, 1295-1297 (2003).
24. Campana C, Regazzi MB, Buggia I, Molinaro M: Clinically significant drug interactions with cyclosporin: an update. Clin. Pharmacokinet. 30(2), 141-179 (1996).
25. Saeki T. Ueda K, Tanigawara Y. Hori R, Komano T: Human P-glycoprotein transports cyclosporin A and FK506. J. Biol. Chem. 268(9), 6077-6080 (1993).
26. Dai Y, Iwanaga K, Lin YS et al.: In vitro metabolism of cyclosporine A by human kidney CYP3A5. Biochem Pharmacol. 68, 1889-1902(2004).
27. Zhang Y, Benet LZ: The gut as a barrier to drug absorption: combined role of cytochrome P450 3A and P-glycoprotein. Clin. Pharmacokinet. 40(3), 159-168 (2001).
28. Hesselink DA, van Gelder T, van Schalk RHN: The pharmacogenetics of calcineurin inhibitorsi one step closer toward Individualized immunosuppression? Pharmacogenomics 6(4), 323-337 (2005).
29. Wojnowski L: Genetics of the variable expression of CYP3A in humans. Ther. Drug Monit. 26(2), 192-199 (2004).
30. Marzolini C, Paus E, Buclin T, Kim RB: Polymorphisms in human MDR1 (P-glycoprotein): recent advances and clinical relevance. Clin. Pharmacol. Ther. 75, 13-33 (2004).
31. Anglicheau D. Legendre C, Beaune P. Thervet E: Cytochrome P450 3A polymorphisms and immunosuppressive drugs: an update. Pharmacogenomics 8(7), 835-849(2007).
32. Thervet E, Anglicheau D, Legendre C, Beaune P: Role of pharmacogenetics of immunosuppressive drugs in organ transplantation. Ther. Drug Monit. 30(2), 143-150 (2008).
33. Anglicheau D, Thervet E. Etienne I et al.: CYP3A5 and MDR1 genotic polymorphisms and cyclosporine pharmacokinetics after renal transplantation. Clin. Pharmacol. Ther. 75, 422-433 (2004).
34. Hesselink DA, van Gelder T, van Schaik RHN et al.: Population pharmacokinetics of cyclosporine in kidney and heart transplant recipients and the influence of ethnicity and genetic polymorphisms in the MDR-1, CYP3A4 and CYP3A5 genes. Clin. Pharmacol. Ther. 76, 545-556 (2004).
35. Eng H-S, Mohamed Z. Calne R et al.: The influence of CYP3A gene polymorphisms on cyclosporine dose requirement in renal allograft recipients. Kidney Int. 69, 1858-1864 (2006).
36. Kearns GL, Abdel-Rahman SM. Alander SW, Blowey DL, Leeder JS, Kauffman RE: Developmental pharmacology drug disposition, action and therapy in Infants and children. N. Engl. J. Med. 349(12), 1157-1167 (2003).
37. de Wildt SN, Kearns GL, Leeder JS, van den Anker IN: Cytochrome P450 3A: ontogeny and drug disposition. Clin. Pharmacokinet. 37(6), 485-505 (1999).
38. Lacroix D, Sonnier M, Moncion A, Cheron G, Cresteil T: Expression of CYP3A in the human liver: evidence that the shift between CYP3A7 and CYP3A4 occurs immediately after birth. Eur. J. Biochem. 247, 625-634 (1997).
39. Stevens JC, Hines RN, Gu C et al.: Developmental expression of the major human hepatic CYP3A enzymes. J. Pharmacol. Exp. Ther. 307, 573-582 (2003).
40. Fakhoury M, Litalien C, Medard Y et al.: Localization and mRNA expression of CYP3A and P-glycoprotein in human duodenum as a function of age. Drug Metab. Dispos. 33, 1603--1607 (2005).
41. Tsai CE, Daood MJ, Lane RH, Hansen TWR, Gruetzmacher EM, Watchko JF: P-glycoprotein expression in mouse brain increases with maturation. Biol. Neonate 81, 58-64 (2002).
42. Haufroid V, Wallemacq P, Van Kerckhove V et al.: CYP3A5 and ABCB1 polymorphisms and tacrolimus pharmacokinetics in renal transplant candidates: guidelines from an experimental study. Am. Transplant 6, 2706-2713 (2006).
43. Michaud J, Dube P, Naud et al.: Effects of serum from patients with chronic renal failure on rat hepatic cytochrome P450. Br J Pharmacol. 144, 1067-1077 (2005).
44. Sun H, Huang Y, Frassetto L, Benet LZ: Effects of uremic toxins on hepatic uptake and metabolism of erythromycin. Drug Metab. Dispos. 32, 1239-1246 (2004).
45. Nolin TD, Appiah K, Kendrick SA, Le P, McMonagle E, Himmelfarb J: Hemodialysis acutely improves hepatic CYP3A4 metabolic activity. J. Am. Soc. Nephrol. 17, 2363-2367 (2006).
46. Naud J, Michaud J, Leblond FA, Lefrancois S, Bonnardeaux A, Pichette V: Effects of chronic renal failure on liver drug transporters. Drug Metab Dispos. 36(1), 124-128 (2008).
47. Hesselink DA, van Schaik RHN, van Agreren M et al.: CYP3A5 genotype is not associated with a higher risk of acute rejection in tacrolimus-treated renal transplant recipients. Pharmacogenet. Genomics 18, 339-348 (2008).
48. Kuypers DRJ, de Jonge H, Naesens M, Lerut E, Verbeke K, Vanrenterghem Y: CYP3A5 and CYP3A4 but not MDR1 single-nucleotide polymorphisms determine long-term tacrolimus disposition and drug-related nephrotoxicity in renal recipients. Clin. Pharmacol. Ther. 82(6), 711-725 (2007).
49. MacPhee IAM, Fredericks S, Tai T et al.: The influence of pharmacogenetics on the time to achieve target tacrolimus concentrations after kidney transplantation. Am. J. Transplant 4, 914 -919 (2004).
50. Hauser IA, Schaeffeler E, Gauer S et al.: ABCB1 genotype of the donor but not of the recipient is a major risk factor for cyclosporine-related nephrotoxicity after renal transplantation. J. Am. Soc. Nephrol. 16, 1501-1511 (2005).
51. Joy MS, Hogan SL, Thompson BD, Firm WF, Nickeleit V: Cytochrome P450 3A5 expression in the kidneys of patients with calcineurin inhibitor nephrotoxicity. Nephrol. Dial. Transplant. 22(7), 1963-1968 (2007).
52. Eap, CB, Bochud M, Elston RC et al.: CYP3A5 and ABCB1 genes influence blood pressure and response to treatment, and their effect is modified by salt. Hypertension 49 (5), 1007-1014 (2007).
53. Crettol S, Venetz J-P, Fontana M et al.: influence of ABCB1 genetic polymorphisms on cyclosporine intracellular concentration in transplant recipients. Pharmacogenet. Genomics 18, 307-315 (2008).
54. Marshall JD, Kearns GL: Developmental pharmacodynamics of cyclosporine. Clin. Pharmacol. Ther. 66, 66-75 (1999).
55. Kavvoura FK, Ioannidis JPA: Methods for meta-analysis in genetic association studies: a review of their potential and pitfalls. Hum. Genet. 123, 1-14 (2008).